Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... For more information, please visit www.cel-sci.com Keywords: AIDS, Acquired Immunodeficiency Syndrome, Adverse Drug Reaction, Arthritis, Biotechnology, ... (NYSE Amex: CVM) announced that Dr. Kenneth S. Rosenthal, Professor of Immunology and Microbiology of Northeastern Ohio Universities College of Medicine and Pharmacy, ... City, Virginia. Working with LEAPS vaccines for herpes simplex virus, HIV, rheumatoid arthritis and most recently, H1N1 influenza, the scientists' studies show ... in collaboration with scientists at the Cleveland Clinic and CEL-SCI on CEL-SCI's LEAPS vaccine technology. The data was presented at the 7th GTCbio Vaccine: "All Things Considered" ...
2009 NOV 16 ... of the HIVvaccine candidates currently in clinical testing. Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Allergies, Allergy Medicine, Biotechnology, ... SAIC-Frederick, Inc. has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute ...
2009 NOV 16 ... "These are exciting times for GeoVax and everyone involved in HIV/AIDSvaccine development," Dr. McNally continued. "The recently announced success of a ...
2009 NOV 16 ... Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the ... Although much attention has focused on the scientific obstacles to developing an HIV vaccine, the Massachusetts Institute of Technology's Jeffrey E. Harris contends that the ...
2009 NOV 23 ... hopes that a protective vaccine can be developed, acquired immunodeficiency syndrome (AIDS) remains a major public health problem. Much has been learned about HIV-1, the virus ... virus that causes the disease. However, basic aspects of person-to-person transmission and of the progressive intercellular infection that depletes the immune system of its vital ...
2009 NOV 23 ... Diseases, Pharmaceutical, Research, Diabetes, S, Conservation, Ecology, Environment, AIDS, Acquired Immunodeficiency Syndrome, Allergies, Allergy Medicine, BioInformatics LLC, ... it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop ... including infections from the influenza viruses and human immunodeficiency virus (HIV). In addition, there is an important need to develop novel adjuvants to support the ... Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of ...
2009 NOV 16 ... Pneumonia takes the lives of more children under 5 than measles, malaria, andAIDS combined. The disease takes the life of one child every 15 seconds, and accounts for 20% ... Medicine, Antibacterial, Antibiotic, Antimicrobial, Biotechnology, Flu, HIB Vaccines, HIV, Haemophilus, Human Immunodeficiency Virus, Hygiene, Immunization, Influenza, Malaria, ... (pneumococcal disease) and Haemophilus influenzae type b (Hib). However, use of Hib vaccine has only recently expanded to low-income countries and pneumococcal vaccine is not yet ...
Subject: The Global Coalition against Child Pneumonia
2009 NOV 16 ... 69-77 Paul Street, London EC2A 4LQ, England. Keywords: Norway, Skien, AIDS, Acquired Immunodeficiency Syndrome, Bionor Immuno AS, Biotechnology, Biotechnology ... virus-like particle (VLP)-CCR5 composition aims to function as either a preventative and/or therapeutic vaccine inducing durable autoantibodies that can block CCR5 and prevent ... "Several new strategies targeting HIV infection aim to inhibit virus entry by blocking the chemokine receptor CCR5 used by ...
2009 NOV 16 ... countries, and collectively cause a health burden comparable to malaria, tuberculosis or AIDS (known as the "Big 3" tropical diseases). The McLaughlin Rotman Centre ... Biotechnology Company, Blindness, Dengue Fever, Diagnostics, Elephantiasis, Filariasis, HIV, Human Immunodeficiency Virus Bacterial Infection, Immunization, Leprosy, Malaria, ... United Cell Biotechnology Co. Ltd. (Shanghai, China) manufactures a novel oral cholera vaccine, as does Shantha Biotechnics (Hyderabad, India), whose product provides longer, broader ...
2009 NOV 16 ... immunodeficiency virus (SIV)-infected African nonhuman primates do not progress to AIDS in spite of high and persistent viral loads (VLs). Some authors consider the high viral ... Biotechnology Business, Biotechnology Company, Body Weight, Genentech Inc., HIV, Human Immunodeficiency Virus, Immunology, Medical Device, Monoclonal Antibodies, Simian ... For additional information, contact I. Pandrea, University of Pittsburgh, Center Vaccine Research, 9045 Biomedial Science Tower 3, 3501 5th Avenue, Pittsburgh, PA 15261, USA. ...
2009 NOV 24 ... Life Sciences, Infectious Diseases, Pediatrics, Virology, Vaccination, Immunization, AIDS, HIV, Sexually Transmitted Disease, Immunology, Acquired Immune Deficiency Syndrome, ... infection with rotavirus annually results in an estimated 611,000 deaths among infants and young children <5 years of age worldwide, and these deaths primarily occur in ... countries, particularly in sub-Saharan Africa and Asia." "The need for a vaccine to reduce the number of deaths caused by rotavirus infection among children in ...
2009 NOV 16 ... 1752 N St. NW, Washington, DC 20036-2904, USA. Keywords: Canada, Hamilton, AIDS, Acquired Immune Deficiency Syndrome, Biotechnology, Clinical Trials, Drug Development, ... type 2 (HSV-2), is one of the most prevalent sexually transmitted diseases worldwide and a risk factor for acquiring human immunodeficiency virus. Although many vaccine ... Acquired Immune Deficiency Syndrome, Biotechnology, Clinical Trials, Drug Development, HIV, HSV-2, Herpes Simplex, Herpes Simplex Virus, Herpes Virus, Herpesvirus, Human ...
2009 NOV 28 ... on these observations are now ongoing in animals."Keywords: Pediatrics, AIDS, Acquired Immunodeficiency Syndrome, Biotechnology, HIV, Human Immunodeficiency Virus, ... A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks ... healthy cells has revealed a new direction for researchers hoping to design an effective vaccine."Our study clearly showed that we've been overlooking a very important ...
2009 NOV 16 ... 350 Main St., Malden 02148, MA, USA. Keywords: United States, Southborough, AIDS, Acquired Immunodeficiency Syndrome, Cytometry, HIV, Human Immunodeficiency Virus, ... "Pathogenic HIV and SIV infections characteristically deplete central memory CD4+ T cells and induce chronic ... Research, Virology, Harvard University. This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2009, AIDS Vaccine Week via ...
2009 NOV 16 ... N St. NW, Washington, DC 20036-2904, USA. Keywords: United States, Seattle, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Biotechnology, ... virus type 1 (HIV-1) infection in highly exposed seronegative (ES) individuals and the later clinical consequences of breakthrough infection can provide insight into ... infection can provide insight into strategies to control HIV-1 with an effective vaccine. From our Seattle ES cohort, we identified one individual (LSC63) who seroconverted ...
2009 NOV 16 ... who need it most. Keywords: Child Immunization, Pediatrics, Vaccination, AIDS, Acquired Immunodeficiency Syndrome, Biotechnology, Clinical Research, Clinical Trial ... in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, ... co-inventor of RTS,S and Vice President of R&D, Vaccines for Emerging Diseases and HIV, at GSK Biologicals. "The Phase III trial is a huge undertaking that ... A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, ...
2009 NOV 16 ... of new treatments for HIV potentially slowing - or even preventing - the onset of AIDS. The trial makes use of the body's natural ability to recognise infected ... Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, announced the approval of an ... over 33 million people estimated to be living with HIV worldwide. No cure or effective vaccine yet exists. Current treatment regimens are based on combinations of different classed of ...
